Serum Institute of India (as Covovax)
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:activeIngredient |
recombinant spike protein of SARS-CoV-2
|
| gptkbp:adjuvant |
gptkb:Matrix-M
|
| gptkbp:age |
adults and children (age limits may vary by country)
|
| gptkbp:approvedBy |
December 2021 (India)
|
| gptkbp:associatedWith |
gptkb:Novavax_COVID-19_vaccine
|
| gptkbp:basedOn |
Novavax COVID-19 vaccine (NVX-CoV2373)
|
| gptkbp:brand |
gptkb:Covovax
|
| gptkbp:countryOfOperation |
gptkb:India
|
| gptkbp:emergencyServices |
gptkb:India
|
| gptkbp:form |
suspension for injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
Serum Institute of India (as Covovax)
|
| gptkbp:indication |
prevention of COVID-19
|
| gptkbp:intervalBetweenDoses |
3 weeks
|
| gptkbp:manufacturer |
gptkb:Serum_Institute_of_India
|
| gptkbp:marketedAs |
gptkb:Serum_Institute_of_India
|
| gptkbp:numberOfDoses |
2
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:storage |
2–8°C
|
| gptkbp:type |
protein subunit vaccine
|
| gptkbp:WHOEmergencyUseListing |
yes
|
| gptkbp:bfsParent |
gptkb:Nuvaxovid
|
| gptkbp:bfsLayer |
6
|